WT1 Antikörper (AA 277-495)
Kurzübersicht für WT1 Antikörper (AA 277-495) (ABIN1886304)
Target
Alle WT1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 277-495
-
Aufreinigung
- Purified by antigen-affinity chromatography.
-
Immunogen
- Recombinant protein fragment contain a sequence corresponding to a region within amino acids 277 and 495 (P19544) of Wilms Tumor 1
-
-
-
-
Applikationshinweise
-
Suggested dilutions:
Western blotting: 1.500-1.3000
Immunohistochemistry: 1.50-1.500
Immunofluorescence: 1.100-1.200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- 0.1 M Tris-buffered saline with 10 % Glycerol (pH 7.0).0.01 % Thimerosal was added as a preservative.
-
Konservierungsmittel
- Thimerosal (Merthiolate)
-
Vorsichtsmaßnahmen
- Biohazard Informations: This product contains thimerosal which is hazardous.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
-
-
- WT1 (Wilms Tumor 1 (WT1))
-
Andere Bezeichnung
- WT1
-
Hintergrund
-
This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus.It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors.Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized.There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms.Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.[provided by RefSeq]
-
Molekulargewicht
- 56 kDa
-
Gen-ID
- 7490
-
NCBI Accession
- NM_024426, NP_077744
-
Pathways
- Tube Formation
Target
-